Emmanuel Parkay Oladokun

Computational Identification of YQG-Like Small-molecule Inhibitors Targeting TIM-3 for Cancer Immunotherapy

Winner Amaka Egejuru, Abel Ujaigbe Egbemhenghe, Bamidele Samson Omotara, Christiana Oluwaseun Aderemi, Ibidun Blessing Isaac, Emmanuel Parkay Oladokun, Pruthvirajsinh Rajendrasinh Solanki, Ihunanya Meejay Kanu, Christopher Ddamulira, Ibrahim Tope Abdulrasaq, Yemisi Elizabeth Asibor, Onyinyechi Vera Ofoegbu, Sheriff Olabisi Ogunyemi, Cyril Obaro Agadagba, Muhammad Qasim Ali & Olajide Enoch Aderemi · International Journal of Biochemistry Research & Review · 2025

Aims: To identify potential small-molecule inhibitors of T-cell immunoglobulin and mucin domain-3 (TIM-3) through computational approaches and evaluate their interactions, stability, and structural dynamics. Study Design: A computational drug discovery study utilizing virtual scr...

Open access Research Article 10.9734/ijbcrr/2025/v34i1955

Unveiling Novel KRAS G12V Inhibitors: A Comprehensive Study Using Computer-aided Drug Design Approach

Amena Khatun Manica, Benedicta Quainoo, Jonathan Cudjoe, Aminat Motunrayo Adekunle, Cyril Agadagba, Temilade Rukayat Adeniran, Oluwatosin Oluwafunmilola Oluwafemi, Ayomide Daniel Oluwafemi, Abasiodiong Ekanem, Hikmat Opeyemi Sulaiman, Farimah Mohammadi, Emmanuel Parkay Oladokun, Mariam Omowunmi Oguntunji & Roheemah Olamide Oni · International Journal of Biochemistry Research & Review · 2025

The KRAS G12V mutation is a formidable oncogenic driver implicated in the pathogenesis of several aggressive cancers, including pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer. Overcoming the historical challenges associated with targeting KRAS...

Open access Research Article 10.9734/ijbcrr/2025/v34i2978